References
- Yun Jeong L, Chang-Hun Y. Non-steroidal anti-inflammatory drug-induced enteropathy. Clin Endosc. 2012;45(2):138–144.
- Freeman HJ. Drug-induced Sprue-like intestinal disease. Int J Celiac Dis. 2014;2(2):49–53.
- Ianiro G, Bibbò S, Montalto M, et al. Systematic review: sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40(1):16–23.
- Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with Olmesartan. Mayo Clin Proc. 2012;87(8):732–738.
- Cartee AK, Nadeau A, Rubio-Tapia A, et al. Characterizing olmesartan-induced enteropathy risk factors, severity, and symptoms resolution, a follow-up to the 2012 case series. Gastroenterology. 2014;146(5):S-603–S-604.
- Marthey L, Cadiot G, Seksik P, et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014;40(9):1103–1109.
- Choi E-YK, Mc Kenna BJ. Olmesartan-associated enteropathy. A review of clinical and histologic findings. Arch Pathol Lab Med. 2015;139(10):1242–1247.
- Nielsen JA, Steephen A, Lewin M. Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug. World J Gastroenterol. 2013;19(40):6928–6930.
- Mondet L, Pierson-Marchandise M, Gras V, et al. Angiotensin II receptor blockers-induced enteropathy: not just olmesartan! A case report with candesartan. Fund Clin Pharmacol. 2016;30:62.
- Maier H, Hehemann K, Vieth M. Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan. Cesk Patol. 2015;51(2):87–88.
- Cammarota G, Ianiro G, Bibbò S, et al. Letter: telmisartan associated enteropathy - is there any class effect? Authors’ reply. Aliment Pharmacol Ther. 2014;40(5):570.
- Negro A, Rossi GM, Santi R, et al. A case of severe sprue-like enteropathy associated with losartan. J Clin Gastroenterol. 2015;49(9):794.
- Herman ML, Rubio-Tapia A, Wu -T-T, et al. A case of severe sprue-like enteropathy associated with valsartan. ACG Case Rep J. 2015;2(2):92–94.
- Vasatko T, Machac J, Cyrany J, et al. Letter: telmisartan associated enteropathy - is there any class effect? Aliment Pharmacol Ther. 2014;40:569–570.
- Basson M, Mezzarobba M, Weill A, et al. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut. 2016;65(10):1664–1669.
- Greywoode R, Braunstein ED, Arguelles-Grande C, et al. Olmesartan, other antihypertensives and chronic diarrhea among patients undergoing endoscopic procedures: a case-control study Mayo Clinic Proc. 2014;89(9):1239–1243.
- Katz P, Pegoraro V, Liedgens H. Characteristics, resource utilization and safety profile of patients prescribed with neuropathic pain treatments: a real-world evidence study on general practices in Europe. Curr Med Res Opin. 2017;33:1481–1489.
- DeGaetani M, Tennyson CA, Lebwohl B, et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013;108(5):647–653.
- del Farmaco, A. I. (2014). L’uso dei farmaci in Italia. Rapporto nazionale anno 2012. Osservatorio Nazionale sull’impiego dei Medicinali, OsMed. Roma, (2013).
- Dietlein G, Schr€oder-Bernhardi D. Use of the mediplus patient database in healthcare research. Int J Clin Pharmacol Ther. 2002;40(3):130–133.
- Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009;47(10):617–626.